Phanes Therapeutics Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate PT886 in Combination with KEYTRUDA® for Claudin 18.2-Positive Gastric and Gastroesophageal Junction Cancers

After 4 years of refinement, the largest IP in China's oncolytic virus field is重磅来袭!

On October 16, 2023, a clinical-stage biotechnology company focused on the discovery and development of innovative drugs in the field of oncologyPhanes Therapeutics, Inc. announces clinical collaboration agreement with MSDTo study the combination of Phanes Therapeutics' first-in-class Claudin 18.2/CD47 bispecific antibody PT886 and MSD's PD-1 inhibitor KEYTRUDA® (pembrolizumab) in Claudin 18.2-positive gastric cancer or gastroesophageal junction (GEJ) cancer patients. PT886 was developed using Phanes Therapeutics’ proprietary bispecific antibody technology platforms, PACbody™ and SPECpair™, and received Orphan Drug Designation from the FDA last year.

Phanes Therapeutics is currently conducting a multicenter Phase I clinical trial of PT886 in the United States to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PT886 in patients with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, and pancreatic cancer. These patients have experienced disease progression after receiving available standard therapies, or the standard therapies have been proven ineffective, intolerable, or considered inappropriate (NCT05482893). The next phase of Phanes Therapeutics' research will explore the therapeutic potential of PT886 in combination regimens for gastric cancer, gastroesophageal junction cancer, and pancreatic cancer. The clinical collaboration with MSD will assess the use of PT886 in combination with KEYTRUDA® in claudin 18.2-positive gastric cancer or gastroesophageal junction cancer patients, with or without chemotherapy.

About PT886

PT886 is a first-in-class bispecific antibody targeting claudin 18.2 and CD47. Constructed using Phanes Therapeutics' proprietary bispecific antibody technology platforms, PACbody™ and SPECpair™, PT886 has been granted Orphan Drug Designation by the FDA for the treatment of pancreatic cancer. PT886 directly kills tumor cells through macrophage phagocytosis (ADCP activity) and natural killer cell cytotoxicity (ADCC activity). By simultaneously targeting claudin 18.2 and CD47 expressed on the surface of tumor cells, PT886 broadens the scope of tumor killing. Additionally, PT886 is expected to induce the presentation of tumor neoantigens by guiding tumor cells into phagocytic antigen-presenting cells (APCs), and indirectly activate T-cell-mediated killing of claudin 18.2-expressing tumor cells via recognition of tumor neoantigens, thereby stimulating the adaptive immune system. The anti-CD47 arm of PT886 is differentially designed to minimize binding to human red blood cells while maintaining strong binding activity to CD47 on the surface of tumor cells, thus offering an improved benefit/risk profile compared to other CD47 molecules.

About Phanes Therapeutics

Phanes Therapeutics, a clinical-stage biotechnology company, is dedicated to the research and development of innovative drugs in the field of oncology. The company currently has three projects in clinical stages, including the best-in-class monoclonal antibody (mAb) project PT199, and two first-in-class bispecific antibody (bsAbs) projects, PT886 and PT217. Both PT886 and PT217 have received FDA Orphan Drug Designation. The company's R&D pipeline also includes humanized monoclonal antibodies, biparatopics bispecific antibodies, and single-chain variable fragments (scFvs) targeting various tumor-associated antigens (TAAs), suitable for ADC and CAR-T applications.

Pipeline under research

Phanes Therapeutics has established a robust R&D pipeline through its proprietary technology platforms, PACbody™, SPECpair™, and ATACCbody™, to develop novel biologics addressing highly unmet medical needs in the field of oncology. PACbody™ is a proprietary approach that does not require protein engineering to construct bispecific antibodies, allowing the antibody molecules to maintain their natural structure with superior CMC properties. The SPECpair™ technology platform enables the production of bispecific antibodies with a native IgG structure using traditional monoclonal antibody manufacturing processes. The ATACCbody™ technology platform is a proprietary method that targets solid tumors with immuno-oncology molecules whose activity can be modulated, aiming to minimize the risk of cytokine release syndrome.

Disclaimer:

The content of the article is for reference only and does not constitute investment advice. Investors who take actions based on this information bear their own risks. The article maintains a neutral stance regarding statements and viewpoints, and does not provide any explicit or implicit guarantees concerning the accuracy, reliability, or completeness of the content included. Readers are advised to use the information as a reference only and assume full responsibility for their actions. The various articles published by this public account aim to share information, and if there is any infringement, please contact us and we will delete them.

Contact Us

Registration is about to close.

Scan to consult immediately

Phone: 13816031174 (Same as WeChat)

Click here "Read More" to enter the registration and participation channel